Q4 2025 earnings call: 2026 revenue guidance $52–$56M, IRRAS integration, FDA updates, and growth outlook—read key takeaways.

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2025 Earnings Call Transcript March 17, 2026 ClearPoint Neuro, Inc. misses on ...

ClearPoint Neuro lost more than 14% on Wednesday after its FY26 revenue guidance fell short of analysts’ estimates. The stock ...

Thank you. This is one of the largest unmet needs in all of medicine, and we at ClearPoint Neuro, Inc. believe we can play a ...

ClearPoint Neuro CLPT recently announced the full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System. The newly launched technologies are likely to be on ...

Deep Sail Capital, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The fund returned 5.8% net of fees in the third quarter, ...

ClearPoint Neuro, Inc. CLPT, a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, recently received FDA’s 510(k) clearance for its ClearPoint ...

ClearPoint Neuro Inc. (NASDAQ:CLPT) shares are trading higher Wednesday after the company announced results from a Phase I-II clinical study evaluating its ClearPoint Prism Neuro Laser Therapy System.

ClearPoint Neuro, Inc. (NASDAQ: CLPT) on Friday said it received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2. The ClearPoint Navigation Software Version 3.0.2 has been ...